Glanzmann's thrombasthenia risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (6 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glanzmann's thrombasthenia}} | {{Glanzmann's thrombasthenia}} | ||
{{CMG}} {{AE}}{{OK}} | |||
==Overview== | ==Overview== | ||
The most potent risk factor in the [[heritable]] Glanzmann thrombasthenia is [[Consanguineous|consanguineous marriage]]. | The most potent risk factor in the [[heritable]] [[Glanzmann's thrombasthenia]] is [[Consanguineous|consanguineous marriage]]. [[Autoantibodies]] production cause of acquired [[Glanzmann's thrombasthenia|Glanzmann thrombasthenia]]. | ||
Autoantibodies production cause of acquired Glanzmann thrombasthenia . | |||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors that increase [[autoantibodies]] production in [[acquired]] Glanzmann thrombasthenia include: | Common risk factors that increase [[autoantibodies]] production in [[acquired]] [[Glanzmann's thrombasthenia|Glanzmann thrombasthenia]] include: | ||
* [[Hematologic disorders]] and [[malignancies]], such as : | * [[Hematologic disorders]] and [[malignancies]], such as :<ref name="pmid16722529">{{cite journal |vauthors=Nurden AT |title=Glanzmann thrombasthenia |journal=Orphanet J Rare Dis |volume=1 |issue= |pages=10 |date=April 2006 |pmid=16722529 |pmc=1475837 |doi=10.1186/1750-1172-1-10 |url=}}</ref> | ||
# [[ | # [[Acute lymphoblastic leukemia]] | ||
# [[ | # [[Non-Hodgkin’s lymphoma]] | ||
# [[ | # [[Multiple myeloma]] | ||
# [[ | # [[Hairy cell leukemia]] | ||
# [[ | # [[Myelodysplastic syndrome]] | ||
# [[ | # [[Immune thrombocytopenic purpura]] ([[ITP]]) | ||
* Autoimmune diseases | * [[Autoimmune diseases]] such as [[Systemic lupus erythematosus|Lupus]] <ref name="pmid24979837">{{cite journal| author=Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A| title=Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies. | journal=Isr Med Assoc J | year= 2014 | volume= 16 | issue= 5 | pages= 307-10 | pmid=24979837 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24979837 }}</ref> | ||
* Drugs : | * Drugs : Anti-thrombotic drugs use , like [[abciximab]], [[eptifibatide]], and [[tirofiban]] which all antagonize [[αIIbβ3]] | ||
* | * Platelet [[transfusions]]. <ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | ||
==References== | ==References== | ||
| Line 26: | Line 24: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 21:52, 29 July 2020
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia risk factors On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia risk factors |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
The most potent risk factor in the heritable Glanzmann's thrombasthenia is consanguineous marriage. Autoantibodies production cause of acquired Glanzmann thrombasthenia.
Risk Factors
Common risk factors that increase autoantibodies production in acquired Glanzmann thrombasthenia include:
- Hematologic disorders and malignancies, such as :[1]
- Acute lymphoblastic leukemia
- Non-Hodgkin’s lymphoma
- Multiple myeloma
- Hairy cell leukemia
- Myelodysplastic syndrome
- Immune thrombocytopenic purpura (ITP)
- Autoimmune diseases such as Lupus [2]
- Drugs : Anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3
- Platelet transfusions. [3]
References
- ↑ Nurden AT (April 2006). "Glanzmann thrombasthenia". Orphanet J Rare Dis. 1: 10. doi:10.1186/1750-1172-1-10. PMC 1475837. PMID 16722529.
- ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). "Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies". Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.